Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment
Authors
Keywords
-
Journal
BRITISH JOURNAL OF DERMATOLOGY
Volume 169, Issue 5, Pages 992-999
Publisher
Wiley
Online
2013-07-16
DOI
10.1111/bjd.12517
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study
- (2013) Désirée van der Heijde et al. ARTHRITIS AND RHEUMATISM
- Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial
- (2013) Gerd R Burmester et al. LANCET
- JAKs and STATs in Immunity, Immunodeficiency, and Cancer
- (2013) John J. O'Shea et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study
- (2012) K.A. Papp et al. BRITISH JOURNAL OF DERMATOLOGY
- Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
- (2012) Roy Fleischmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis
- (2012) Ronald F. van Vollenhoven et al. NEW ENGLAND JOURNAL OF MEDICINE
- Erythroid Disturbances Before and After Treatment of Portuguese Psoriasis Vulgaris Patients
- (2011) Susana Coimbra et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- IL-6 plays an essential role in neutrophilia under inflammation
- (2011) Misato Hashizume et al. CYTOKINE
- Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis
- (2011) A. M. Lin et al. JOURNAL OF IMMUNOLOGY
- Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550)
- (2011) Kamran Ghoreschi et al. JOURNAL OF IMMUNOLOGY
- Linking interleukin-6 receptor blockade with tocilizumab and its hematological effects using a modeling approach
- (2011) Leonid Gibiansky et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Interleukin-5 and IL-5 receptor in health and diseases
- (2011) Kiyoshi TAKATSU PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL SCIENCES
- Selective functional inhibition of JAK-3 is sufficient for efficacy in collagen-induced arthritis in mice
- (2010) Tsung H. Lin et al. ARTHRITIS AND RHEUMATISM
- Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis
- (2010) Debra M Meyer et al. Journal of Inflammation-London
- New Insights in the Immunologic Basis of Psoriasis
- (2010) Kristine E. Nograles et al. SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
- Quantitative Analysis of Mechanisms That Govern Red Blood Cell Age Structure and Dynamics during Anaemia
- (2009) Nicholas J. Savill et al. PLoS Computational Biology
- IL-5 and eosinophilia
- (2008) Kiyoshi Takatsu et al. CURRENT OPINION IN IMMUNOLOGY
- The JAK-3 inhibitor CP-690550 is a potent anti-inflammatory agent in a murine model of pulmonary eosinophilia
- (2008) Elizabeth Kudlacz et al. EUROPEAN JOURNAL OF PHARMACOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now